

## (12) United States Patent **Ehrich**

#### US 7,919,499 B2 (10) Patent No.: (45) **Date of Patent:** Apr. 5, 2011

#### (54) NALTREXONE LONG ACTING FORMULATIONS AND METHODS OF USE

(75) Inventor: Elliot Ehrich, Lincoln, MA (US)

(73) Assignee: Alkermes, Inc., Waltham, MA (US)

(\*) Notice: Subject to any disclaimer, the term of this

patent is extended or adjusted under 35 U.S.C. 154(b) by 1673 days.

(21) Appl. No.: 11/083,167

Mar. 17, 2005 (22)Filed:

#### **Prior Publication Data** (65)

US 2005/0245558 A1 Nov. 3, 2005

#### Related U.S. Application Data

(60) Provisional application No. 60/564,542, filed on Apr. 22, 2004.

(51)	Int. Cl.	
	A61K 31/44	(2006.01)
	A61K 31/56	(2006.01)
	A01N 43/42	(2006.01)
	A01N 45/00	(2006.01)
	A61F 13/00	(2006.01)

- (52) **U.S. Cl.** ...... **514/282**; 514/171; 424/422
- (58) Field of Classification Search ...... 514/282, 514/171; 424/422

See application file for complete search history.

#### (56)References Cited

#### U.S. PATENT DOCUMENTS

A	1/1988	Arvidsson et al.
A	11/1989	Sinclair
A	4/1995	Tice et al.
A	4/1996	Dante
A	8/1997	Herbert et al.
A	8/1998	Rickey et al.
A *		Chandrashekar et al 424/426
В1		Wright et al.
В1	10/2001	Tice et al.
В1	3/2002	Herbert et al.
В1		Tice et al.
A1	8/2004	Pauletti et al.
	A A A A A B1 B1 B1	A 11/1989 A 4/1995 A 4/1995 A 8/1997 A 8/1998 A * 11/2000 B1 7/2001 B1 10/2001 B1 3/2002 B1 12/2002

### FOREIGN PATENT DOCUMENTS

WO	01/15699	3/2001
WO	01/43726 A	6/2001
WO	WO 2004/064752 A2	8/2004
WO	WO 2004/108084 A2	12/2004

#### OTHER PUBLICATIONS

O'Malley, Stephanie S. et al., "Initial and Maintenance Naltrexone Treatment for Alcohol Dependence Using Primary Care vs Specialty Care. A Nested Sequence of 3 Randomized Trials," Arch Intern Med., 163: 1695-1704 (2003).

Latt, Noeline C. et al., "Naltrexone in alcohol dependence: a randomised controlled trial of effectiveness in a standard clinical setting," MJA, 176: 530-534 (2002).

Heinala, Pekka et al., "Targeted Use of Naltrexone Without Prior Detoxification in the Treatment of Alcohol Dependence: A Factorial Double-Blind, Placebo-Controlled Trial." Clinical Psychopharmacology, 21(3):287-292 (2001).

"Evidence for the Efficacy of Naltrexone in the Treatment of Alcohol Dependence (Alcoholism)," Addiction Treatment Forum, Ed., Leavitt, Stewart, pp. 1-8 (2002). Reuning, R.H., et al., "Pharmacokinetic quantitation of naltrexone release from several sustained-released delivery," NIDA, Research Monograph, Institute on Drug Abuse, 28:172-184, (1981).

Yolles, S., et al., "Long acting delivery for narcotic antagonists II: release reates of naltrexone from Poly(lactic acid) composites," PDA J. of Pharm. Sci and Tech., 64(2):348-349, (1995)

J. of Pharm. Sci and Tech., 64(2):348-349, (1995).
Bartus, et al., Vivitrex®, an Injectable, Extended-Release Formulation of Naltrexone, Provides Pharmacokinetic and Pharmacodynamic Evidence of Efficacy for 1 Month in Rats, Neuropsychopharmacology, 28:1973-1982 (Aug. 2003).
Comer, Sandra D. et al., "Depot Naltrexone: Long-lasting Antagonism of the Effects of Heroin in Humans," Psychopharmacology, 150:251-260 (2003).

159:351-360 (2002).

Chiang, C.N. et al., "Kinetics of a Naltrexone Sustained-release Preparation," Clinical Pharmacology and Therapeutics, 36(5): 704-

U.S. Appl. No. 60/554,658, filed Mar. 19, 2004, Elliott Ehrich, et al. U.S. Appl. No. 60/554,785, filed Mar. 19, 2004, Elliott Ehrich, et al. U.S. Appl. No. 11/082,420, filed Mar. 17, 2005, Elliott Ehrich, et al. U.S. Appl. No. 11/082,534, filed Mar. 17, 2005, Elliott Ehrich, et al. Swift, Robert M., "Drug Therapy for Alcohol Dependence," New England J. of Med., 340(19): 1482-1490 (1999).

Karam-Hage, Maher and Brower, Kirk J., "Gabapentin Treatment for Incompile Associated With Alcohol Dependence," Am. J. Psychiatry.

Insomnia Associated With Alcohol Dependence," Am. J. Psychiatry, 157(1): 151-153 (2000).

Myrick, M.D., Hugh, et al., "Gabapentin Treatment of Alcohol Withdrawal," Am. J. of Psychiatry, 155(11): 1626-1627, (1998). Malcolm, M.D., Robert, et al., "Update on Anticonvulsants for the Treatment of Alcohol Withdrawal," Am. J. on Addictions, 10(1): 16-23, Abstract Only, (2001).

Swift, R., et al., "Naltrexone Effects on Diazepam Intoxication and Pharmacokinetics in Humans," Psychopharmacology, 135(3): 256-262 (1998), Abstract Only.

Chaves, M.L., et al., "Diazepam Inhibits Retroactive Interference of Memory in Humans: Pretreatment with Naltrexone Does Not Alter This Effect," Braz. J. Med. Biol. Res., 23(5): 417-421 (1990), Abstract Only.

Fidecka, S. and Langwinski, R., "Effects of Opioid Antagonists on Anticonvulsant and Hypnotic Activity of Benzodiazepines," Pol. J. Pharmacol., 48(4): 409-414 (1996), Abstract Only.

Longo, L.P., et al., "Divalproex Sodium (Depakote) for Alcohol Withdrawal and Relapse Prevention," J. Addict Dis., 21(2): 55-64

(2002), Abstract Only.

Minuk, G.Y., et al., "The Use of Sodium Valproate in the Treatment of Alcoholism," *J. Addict Dis.*, 14(2): 67-74 (1995), Abstract Only.

Reoux, J.P., et al., "Divalproex Sodium in Alcohol Withdrawal: A Randomized Double Blind Placebo-Controlled Clinical Trial," Alcohol Clin. Exp. Res., 25(9): 1324-1329 (2001), Abstract Only.

#### \* cited by examiner

Primary Examiner — Sreeni Padmanabhan Assistant Examiner — Kendra D Carter

(74) Attorney, Agent, or Firm — Elmore Patent Law Group, P.C.; Carolyn S. Elmore; Darlene A. Vanstone


#### (57)ABSTRACT


The inventions described herein arose from unexpected discoveries made during clinical trials with a long acting formulation of naltrexone. As such, the invention includes a method for treating an individual in need of naltrexone comprising the step of parenterally administering a long acting formulation comprising naltrexone and to the use of naltrexone in the manufacture of medicaments for use in such methods.

#### 15 Claims, 4 Drawing Sheets




Apr. 5, 2011





Apr. 5, 2011





Apr. 5, 2011




FIG.

# DOCKET

# Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

# **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

### **LAW FIRMS**

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

### **FINANCIAL INSTITUTIONS**

Litigation and bankruptcy checks for companies and debtors.

## **E-DISCOVERY AND LEGAL VENDORS**

Sync your system to PACER to automate legal marketing.

